Home' Australian Pharmacist : Australian Pharmacist January 2014 Contents Australian Pharmacist January 2014 I © Pharmaceutical Society of Australia Ltd.
80 Australian Pharmacist January 2014 I © Pharmaceutical Society of Australia Ltd.
in patients with relapsing multiple
sclerosis1 (MS) was PBS listed on
1 December 2013.
Newcastle‐based neurologist Associate
Professor Jeannette Lechner‐Scott who
was involved in the Australian clinical
trials for the new medicine said that
improved access to new options for MS
patients offers hope for the future.
‘Different patients respond to different
medications so having new options is
important in maximising positive results
for patients. Patients have individual
preferences for different modes of
treatment so having access to new oral
medications and different treatment
options is very helpful,’ Professor
As of September 2013, which marked
the six‐month milestone post US
approval, approximately 35,000 patients
had been treated globally with Tecfidera.
diet and exercise do not provide adequate
glycaemic control, as add on to metformin,
a sulphonylurea, a thiazolidinedione (TZD),
insulin (with or without metformin), or
in combination with metformin and a
TZD when dual therapy does not provide
adequate glycaemic control.
1. Nesina Product Information. Takeda Pharmaceuticals. Sep
2. Pharmaceutical Benefits Advisory Committee. Public
summary document: alogliptin, tablets, 6.25 mg, 12.5 mg, 25
mg Nesina 2013. At: www.pbs.gov.au/info/industry/listing/
3. White WB, Cannon CP, Heller SR, et al. EXamination of
cArdiovascular outcoMes with alogliptIN versus standard
of carE in patients with type 2 diabetes mellitus and acute
coronary syndrome (EXAMINE): Alogliptin after Acute
Coronary Syndrome in Patients with Type 2 Diabetes. NEJM
Biogen Idec Australia
Tecfidera (dimethyl fumarate), an oral
treatment that reduces the frequency of
relapses and delays disability progression
Nesina (alogliptin) was PBS listed on
1 December. According to Takeda
Pharmaceuticals this a new oral
medication indicated to improve
glycaemic control in adults with type 2
diabetes (T2D) when added to other
the first and only DPP‐4 inhibitor to be
reimbursed second line without the
need to demonstrate contraindication
or intolerance to sulphonylurea
According to Professor Stephen
Colagiuri, Professor of Metabolic Health
at the Institute of Obesity, Nutrition and
Exercise, University of Sydney, Nesina’s
listing is welcome news for many
Australians living with T2D. The listing
widens access to this new treatment
option for approximately 175,000
Australians living with type 2 diabetes
who may be eligible for this treatment.
However, doctors are encouraged to
consider the needs and preferences of
each patient and provide individualised
treatment,’ he said.
Results from the cardiovascular safety
outcomes trial – EXAMINE – published
in the New England Journal of Medicine
in October 2013, showed that Nesina
demonstrates CV safety outcomes in
people with T2D with recent acute
coronary syndrome (ACS).
Nesina is a DPP‐4 for the treatment of
type 2 diabetes in adults as an adjunct
to diet and exercise. DPP‐4s slow the
inactivation of incretin hormones GLP‐1
and GIP. As a result, an increased amount
of active incretins enables the pancreas
to secrete insulin in a glucose‐dependent
manner, thereby assisting in the
management of blood glucose levels. It is
indicated to improve glycaemic control in
patients ≥18 years old with T2DM when
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Links Archive Australian Pharmacist December 2013 Australian Pharmacist February 2014 Navigation Previous Page Next Page